BEC HCl

Research use only, not for human use.

BEC HCl is a competitive arginase inhibitor, which bind slowly. Ki of BEC HCl is 0.31 μM (pH7.5) for Arginase II, and is 0.4-0.6 μM for rat Arginase I.

BEC HCl is a competitive arginase inhibitor, which bind slowly. Ki of BEC HCl is 0.31 μM (pH7.5) for Arginase II, and is 0.4-0.6 μM for rat Arginase I.

The X-ray crystal structure of the arginase-BEC complex has been determined at 2.3 ? resolution from crystals perfectly twinned by hemihedry. The structure of the complex reveals that the boronic acid moiety undergoes nucleophilic attack by metal-bridging hydroxide ion to yield a tetrahedral boronate anion that bridges the binuclear manganese cluster, thereby mimicking the tetrahedral intermediate (and its flanking transition states) in the arginine hydrolysis reaction.

Administration of the arginase inhibitor BEC decreases arginase activity and causes alterations in NO homeostasis, which are reflected by increases in S-nitrosylated and nitrated proteins in the lungs from inflamed mice. BEC enhances perivascular and peribronchiolar lung inflammation, mucus metaplasia, NF-κB DNA binding, and mRNA expression of the NF-κB-driven chemokine genes CCL20 and KC, and leads to further increases in airways hyperresponsiveness. Animal Model:C57BL/6J wild-type mice, mice deficient in arginase 2 (Arg2-/-), mice deficient in both arginase 1 and 2 (Arg1-/-Arg2-/-), and mice deficient in NOX2 (NOX2-/-Dosage:20 mg/kg. Administration:I.V., in 0.9% saline, 1 hour before the injection of LPS.Result:BEC robustly reduced VEGF expression in neuroglia (72% reduction) and macrophage/microglia (87% reduction).

——

GPCR/G Protein

Antibacterial

Arginase-2| rat Arginase I

Cancer

——

222638-67-7

229.49

C5H12BNO4S·ClH

>98% (HPLC)

H2O : ≥ 35 mg/mL; 152.51 mM

C(=O)([C@H](CSCCB(O)O)N)O.Cl

——

(-20℃)

With Ice Pack

≥ 2 years